Chinese PE Multimodality Imaging Artificial Intelligence Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Artificial Intelligence: AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results

Study summary

The CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE) is a prospective observational multi-center study that will collect imaging text data and raw data of patients with pulmonary embolism (PE) in China. By combining artificial intelligence technology, it aims to identify imaging markers to assist in early diagnosis, differential diagnosis, risk stratification, and prognosis assessment of PE.

Eligibility

Primary outcome measure(s)

• Diagnostic rate of PE — 2 years
  Comparison before and after AI technique.
• APE risk stratification rates (low, intermediate low, intermediate high and high risk) — 2 years
  Comparison before and after AI technique.
• Disease severity of chronic thromboembolic pulmonary disease (CTEPD)/chronic thromboembolic pulmonary hypertension (CTEPH) — 2 years
  Comparison before and after AI technique. Assessment of disease severity is comprehensive, referring to the comprehensive risk assessment in pulmonary arterial hypertension (three-strata model) \[DOI: 10.1183/13993003.00879-2022\], including clinical observations and modifiable variables. The higher the score, the more severe the condition.
• 30 day mortality — 2 years
  Patient mortality (death) at 30-days post-PE diagnosis. Comparison before and after AI technique.

Trial sites (1)

More China-Japan Friendship Hospital trials in China

Other trials for the same condition